Combination bph therapy with fexapotide triflutate, a 5-ari, and an alpha blocker
AssigneeNymox Corporation
InventorPaul Averback
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating benign prostatic hyperplasia that include administering a composition containing at least Fexapotide Triflutate (FT), and subsequently administering one or more compositions containing a 5 α-reductase inhibitor (5-ARI) and an alpha1-adrenergic receptor blocker (alpha blocker). The methods provide dramatically improved mean IPSS values, when compared to the average mean IPSS of the individual actives alone, or when compared to the average mean IPSS of (a) the composition containing FT; and (b) the combination of 5-ARI and alpha blocker.
Claims14
A method of treating a mammal having benign prostatic hyperplasia (BPH) who had not previously taken oral medications for BPH comprising:
- Identifying mammals having BPH who had not previously taken oral medications for BPH;
- administering by intraprostatic injection a composition comprising Fexapotide Triflutate (FT);
- and
- administering at least once daily a 5 α-reductase inhibitor (5-ARI) and an alpha1-adrenergic receptor blocker (alpha blocker) at a period of time of from about 2 months to about 4 years after administration of the composition comprising FT.
A method of treating a mammal having benign prostatic hyperplasia (BPH) who had not previously taken oral medications for BPH comprising:
- Identifying mammals having BPH who had not previously taken oral medications for BPH;
- administering a course of antibiotics to the identified mammals for at least two weeks;
- administering by intraprostatic injection about 10 ml of a composition comprising about 0.25 mg/ml of Fexapotide Triflutate (FT) after administering the course of antibiotics;
- and
- administering at least once daily from about 0.25 to about 5 mg of a 5 α-reductase inhibitor (5-ARI) and from about 0.25 to about 15 mg of an alpha1-adrenergic receptor blocker (alpha blocker) at a period of time from about 2 months to about 4 years after administration of the composition comprising FT.
Dependencies are inferred from the claim text.